Viking Therapeutics announces $550M public offering of common stock at $85.00 per share.

Viking Therapeutics, a clinical-stage biopharmaceutical company, has announced the pricing of a $550M public offering of common stock at $85.00 per share, aiming to raise gross proceeds of approximately $550M. The offering allows Viking to advance its pipeline of novel therapies for metabolic and endocrine disorders. The offering is expected to close on March 4, 2024, subject to customary closing conditions.